Trials / Completed
CompletedNCT00373490
A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
MK0683 Phase1 Clinical Study - Solid Tumor -
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vorinostat | 600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest. |
| DRUG | Vorinostat | 400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days. |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-09-08
- Last updated
- 2015-08-27
- Results posted
- 2009-05-20
Source: ClinicalTrials.gov record NCT00373490. Inclusion in this directory is not an endorsement.